冠心病中与药物闪烁显像相关的心脏型脂肪酸结合蛋白
Heart type fatty acid binding protein in relation to pharmacologic scintigraphy in coronary artery disease.
作者信息
Sbarouni Eftihia, Georgiadou Panagiota, Koutelou Maria, Constantinos Mihas, Chaidaroglou Antigoni, Degiannis Demitris, Voudris Vassilis
机构信息
2 nd Department of Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou Avenue, 17674 Athens, Greece.
出版信息
Clin Chem Lab Med. 2011 Oct 25;50(2):387-90. doi: 10.1515/CCLM.2011.753.
BACKGROUND
Heart-type fatty acid-binding protein (H-FABP) is a marker of myocardial necrosis, but whether it increases during myocardial ischemia is not known. This study investigated whether serum levels of H-FABP change during adenosine stress testing and nuclear imaging in patients with stable coronary artery disease.
METHODS
Thirty stable patients with established coronary artery disease on their medications were studied. Sampling was performed before the stress test, at the end of adenosine infusion, as well as 1, 2 and 3 h after the completion of the infusion.
RESULTS
No difference in H-FABP serum levels were found at the five pre-specified time points in the overall group (p=0.99); furthermore, there was no significant difference regardless of the test result--positive (p=1) or negative (p=0.98).
CONCLUSIONS
It is concluded that H-FABP does not change significantly during pharmacologic stress testing in patients with known coronary artery disease and there is no difference whether there is inducible ischemia or not.
背景
心脏型脂肪酸结合蛋白（H-FABP）是心肌坏死的标志物，但在心肌缺血期间其是否升高尚不清楚。本研究调查了稳定型冠心病患者在腺苷负荷试验和核成像过程中血清H-FABP水平是否发生变化。
方法
对30例正在服用药物的稳定型冠心病患者进行研究。在负荷试验前、腺苷输注结束时以及输注完成后1、2和3小时进行采样。
结果
在整个研究组的五个预先设定的时间点，H-FABP血清水平没有差异（p = 0.99）；此外，无论试验结果是阳性（p = 1）还是阴性（p = 0.98），均无显著差异。
结论
得出结论，已知冠心病患者在药物负荷试验期间H-FABP无显著变化，无论是否存在诱发性缺血均无差异。
Zotero 插件